Articles

With the approval of the Sapien valve in November 2011, transcatheter aortic valve implantation (TAVI) technology is expected to revolutionize heart valve replacement with a minimally invasive...

Recently, the U.S. Food and Drug Administration (FDA) has approved the Edwards Sapien transcatheter heart valve for patients with aortic stenosis (AS), who are not suitable for standard aortic...

Within the United States, the anticipated approval and launch of  TAVR has received considerable attention, with speculation about who will perform the procedure. For example, many physicians...

Each year I attend Transcatheter Cardiovascular Therapeutics (TCT), I comb the event and its sessions looking for the next big trend or technological innovations in cardiovascular devices. Below...

The U.S. Food and Drug Administration (FDA) today approved the first transcatheter aortic heart valve in the United States - the Sapien THV. Experts say the approval will open a new chapter in how...

A better strategy to sell the costs of a transcatheter aortic valve implantation (TAVI) program to hospital administrators is not to base ROI on TAVI procedures, but on the increased surgical...

In a closely watched move – viewed as a big step toward a paradigm shift in how heart valves are repaired in the United States – a U.S. Food and Drug Administration (FDA) advisory panel in July...

One of the biggest trends is the creation of hybrid operating rooms (ORs) that bring together the best of both surgical and interventional technologies. They are centered around a high-quality...

August 30, 2011 – Results from a study presented at the European Society of Cardiology (ESC) Congress 2011 show that transcatheter aortic-valve implantation (TAVI) in low-risk patients met...

CoreValve prosthesis

August 30, 2011 – Single center data of the German Heart Centre in Munich demonstrate a sustained improvement of hemodynamic values up to three years after CoreValve implantation. There are no...